Unknown PHASE1 INTERVENTIONAL 1-arm NCT03241784

T-Regulatory Cells in Amyotrophic Lateral Sclerosis

Expansion and Infusion of T-Regulatory Cells in Amyotrophic Lateral Sclerosis

Sponsor: Stanley H. Appel, MD

Conditions ALS (Amyotrophic Lateral Sclerosis)

Interventions Autologous T-regulatory lymphocytes Interleukin-2

Updated 8 times since 2017 Last updated: Mar 23, 2018 Started: May 16, 2016 Primary completion: Feb 28, 2018 Completion: Mar 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03241784, this PHASE1 trial focuses on ALS (Amyotrophic Lateral Sclerosis) and remains ongoing. Sponsored by Stanley H. Appel, MD, it has been updated 8 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jan 2021 — Oct 2021 [monthly]

Unknown Status PHASE1
Apr 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Active Not Recruiting → Unknown Status

▶ Show 3 earlier versions

Jun 2018 — Apr 2020 [monthly]

Active Not Recruiting PHASE1
Apr 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE1
Sep 2017 — Apr 2018 [monthly]

Active Not Recruiting PHASE1

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stanley H. Appel, MD

Data source: The Methodist Hospital Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States